Retrospective Review of Esophageal Cancer at MSKCC
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 4,000
- Locations
- 1
- Primary Endpoint
- . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
Study Overview
Brief Summary
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
- •Pathologic staged T3 tumors (pT3)
Exclusion Criteria
- •Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
- •Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
- •Patients undergoing salvage esophagectomy
- •Evidence of distant metastatic disease
- •Patients with a positive proximal or distal margin
Arms & Interventions
Circumferential resection margin (CRM)
Participants will have a diagnosis of esophageal carcinoma and residual tumor >1 mm from the CRM
Intervention: Esophagectomy (Procedure)
Circumferential resection margin (CRM)-close
Participants will have a diagnosis of esophageal carcinoma and residual tumor >0-1 mm from the CRM
Intervention: Esophagectomy (Procedure)
Circumferential resection margin (CRM)+
Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM
Intervention: Esophagectomy (Procedure)
Outcomes
Primary Outcomes
. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
Time Frame: Up to 2 years
Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.
Secondary Outcomes
- Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).(Up to 2 years)
- Overall survival and progression-free survival (measured from date of surgery)(Up to 2 years)
- Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).(Up to 2 years)
- Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).(Up to 2 years)